TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Stock Information for TriSalus Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TriSalus Life Sciences Inc.

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
TriSalus Life Sciences Proposes Public Offering
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery(TM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.